References
- 1. Blachier M, Leleu H, Peck-Radosavljevic M. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatology, 58, 2013, № 3, 593-608.
- 2. Elpek G. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol, 20, 2014, № 23, 7260-7276.
- 3. Göbel T, Erhardt A, Herwig M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol, 83, 2011, № 6, 968-973.
- 4. Hernandez-Gea V, Scott L. Friedman SL. Pathogenesis of Liver Fibrosis: mechanisms of disease. Ann Rev Pathol, 6, 2011, № 2, 425-456.
- 5. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis. Biochim Biophys Acta (BBA), 1832, 2013, № 7, 876-883.
- 6. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.
- 7. Rossi E, Adams LA, Bulsara M et al. Assessing Liver Fibrosis with Serum Marker Models. Clin Biochem Rev, 28, 2007, № 1, 3-10.
- 8. Baranova A, P. La P, A. Birerdinc. Non-invasive markers for hepatic fibrosis. BMC Gastroenterology, 11, 2011, № 1, 91-98.
- 9. Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Adv Hepat, 2014, 2014, Article ID 357287, 15.
- 10. Lombardi R, Buzzetti E, Roccarina D, and Emmanuel A. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol, 21, 2015, № 39, 11044-11052.
- 11. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.
- 12. Gressner, CF Gao, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey. World J Gastroenterol, 15, 2009, № 20, 2433-2440.
- 13. Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx, 1, 2004, № 2, 182-188. doi:10.1602/neurorx.1.2.182.
- 14. Huang H, Wu T Mao J, et al. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. J Integrat Biol, 19, 2015, № 6, 339-345.
- 15. Papastergiou V, Tsochatzis E, Andrew K. Non-invasive assessment of liver fibrosis Ann Gastroenterol, 25, 2012, № 3, 218-231.
- 16. Cox-North PP, Shuhart MC Core Concepts. Evaluation and Staging of Liver Fibrosis. Last Updated: October 22nd, 2015.
- 17. Lurie Y, Webb M, Cytter-Kuint R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol, 21, 2015, № 41, 11567-11583.
- 18. Liu T, Wang X, Karsdal MA, et al. Molecular Serum Markers of Liver Fibrosis. Biomark Insights, 7, 2012, № 1, 105-117.
- 19. Tsochatzis EA, Crossan C Longworth L. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology, 60, 2014, № 3, 832-843.
- 20. Zhang D, Wang NY, Yang CB, et al. The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis. Dig Dis Sci, 55, 2010, № 3, 767-74.
- 21. Leroy V, Monier M, Bottari S, et al. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid Metalloproteinases and Their Inhibitors as Serum Markers. Am J Gastroent, 99, 2004, № 2, 271-279.
- 22. De Lucca Schiavon L, Narciso-Schiavon J, de Carvalho-Filho R et al. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 20, 2014, № 11, 2854-2866.
- 23. Haukeland JW, Lorgen I, Schreiner LT, et al. AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol, 43, 2008, № 10, 1241-1248.
- 24. Lin ZH, Xin YN, Dong QJ et al. Performance of the aspar-tate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology, 53, 2011, № 3, 726-736.
- 25. Wenwen J, Zhonghua L, Yongning X, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis. Gastroenterol, 12, 2012, № 1, 14. Published online 2012 Feb 14. doi: 10.1186/1471-230X-12-14
- 26. Zaman A, Rosen HR, Ingram K et al. Assessment of FIBRO Spect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med, 120, 2007, № 3, 280-291.
- 27. Salkic NN, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol, 109, 2014, № 6, 796-806.
- 28. Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatology, 59, 2013, № 2, 236-242.
- 29. Parkes J, Guha IN, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 47, 2008, № 2, 455-460.
- 30. Guechot J, Trocme C, Renversez JC et al. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 50, 2012, № 4, 693-699.
- 31. Trembling PM, Lampertico P, Parkes J. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat, 21, 2014, № 6, 430-438.
- 32. Boeker KH, Haberkorn CI, Michels D. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta, 316, 2002, № 1-2, 71-81.